Koenders P G, Beex L V, Kienhuis C B, Kloppenborg P W, Benraad T J
Department of Experimental and Chemical Endocrinology, University Hospital, Nijmegen, The Netherlands.
Breast Cancer Res Treat. 1993;25(1):21-7. doi: 10.1007/BF00662397.
The prognostic value of Epidermal Growth Factor Receptor (EGFR) in human breast cancer is a matter of debate. We conducted a prospective study that included 459 unselected patients with primary breast cancer (median follow-up 24 months) to assess the prognostic value of EGFR. EGFR was assessed using a standardized radioligand binding assay. Univariate analysis showed that EGFR is a factor indicative of a poor prognosis with respect to Disease Free Survival (DFS, P = 0.03) and Overall Survival (OS, P = 0.002), if an EGFR level of 50 fmol/mg of membrane protein is introduced as a cut-off for EGFR-positivity. Multivariate analysis showed that EGFR was not an independent factor. This prospective study shows that EGFR, although not an independent factor, is indicative of poor prognosis in human breast cancer.
表皮生长因子受体（EGFR）在人类乳腺癌中的预后价值存在争议。我们开展了一项前瞻性研究，纳入了459例未经挑选的原发性乳腺癌患者（中位随访时间24个月），以评估EGFR的预后价值。采用标准化放射性配体结合试验评估EGFR。单因素分析表明，如果将EGFR水平50 fmol/mg膜蛋白作为EGFR阳性的临界值，那么就无病生存期（DFS，P = 0.03）和总生存期（OS，P = 0.002）而言，EGFR是预后不良的一个指标。多因素分析显示EGFR不是一个独立因素。这项前瞻性研究表明，EGFR虽不是独立因素，但预示着人类乳腺癌的预后不良。
